A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...
Collegium also announced today the appointments of three new executive leaders as the Company drives a new phase of growth: David Dieter, as Executive Vice President, General Counsel; Jane Gonnerman ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results